DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for congenital primary aphakia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital primary aphakia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital primary aphakia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2017 case report describes a 2-month-old male patient with bilateral congenital primary aphakia, microphthalmia, corneal opacity, and anterior segment dysplasia. At age 2, his left eye visual acuity was 20/1000 at 30 cm, he could discriminate red, blue, and yellow light, and a scotopic combined rod-cone electroretinogram recorded a b-wave. The right eye became blind during follow-up. No mutation in the FOXE3 gene was found by Sanger sequencing or whole exome sequencing, suggesting possible genetic heterogeneity despite FOXE3 mutations being a known cause of congenital aphakia. A 2003 retrospective study of 20 aphakic children (mean age 7.7 years, range 4–11) who received 4-point scleral fixation of posterior chamber intraocular lenses reported that after a mean follow-up of 19.35 months, 12 patients (60%) achieved best corrected visual acuity of 6/18 or better. Preoperative acuity was 6/18 or better in 8 eyes (40%). Intraoperative complications included vitreous hemorrhage in 2 eyes and suture slippage in 1 eye. Postoperative complications included mild anterior uveitis in 12 eyes and severe fibrinoid reaction in 8 eyes; no suture exposure, IOL malposition, or infection occurred. The authors note that preexisting amblyopia was a major cause of poor visual outcome.
A 2006 paper on thrombocytopenia and absent radii (TAR) syndrome describes a 6-month-old infant with type III distal phocomelia (hand attached directly to humerus). The authors state that spontaneous remission of thrombocytopenia is expected after 12 months if crises are supported by platelet transfusions, and that these patients have good prognosis for longevity. They recommend whole blood count for any infant with radius aplasia at birth, and that orthopaedic treatment should be planned after the first year when remission is achieved. This paper does not address congenital primary aphakia.
No drug treatment for congenital primary aphakia appears in these abstracts. The 2017 case confirms that even with genetic testing, a FOXE3 coding mutation may be absent, leaving the cause unknown in some patients. The 2003 surgical series shows that visual outcomes after lens implantation are limited by amblyopia, not by the procedure itself. What is missing is any molecular therapy or animal model for the condition, any systematic genetic screening beyond FOXE3 in larger patient cohorts, and any clinical trial design that could test a drug in utero or in early infancy to prevent the developmental defect.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Cataract & Refractive Surgery · 2003 · 29 citations
Four-point fixation of posterior chamber intraocular lenses in children with unilateral aphakia
AbstractPURPOSE: To evaluate the results of 4-point scleral fixation of posterior chamber intraocular lenses (PC IOLs) in children. SETTING: Mansoura Ophthalmic Center, Mansoura University, Mansoura, Egypt. METHODS: This retrospective study comprised 20 aphakic eyes of 20 children. Preoperative investigations proved the absence of adequate posterior capsule support. All patients had ab externo 4-point scleral fixation of a PC IOL. All preoperative and postoperative data were studied and analyzed. RESULTS: The mean preoperative age was 7.7 years (range 4 to 11 years). The mean follow-up was 19.35 months (range 13 to 30 months). The preoperative findings included a best corrected visual acuity of 6/18 or better in 8 eyes (40%), corneal scarring in 18 eyes, sector iridectomy in 7 eyes, and after-cataract in 4 eyes. The intraoperative complications included vitreous hemorrhage in 2 eyes and slippage of 1 suture in 1 eye. Postoperative complications included mild anterior uveitis in 12 eyes and severe fibrinoid reaction in the anterior chamber in 8 eyes. There were no cases of suture exposure, IOL malpositioning, or infection. Twelve patients (60%) had a visual acuity of 6/18 or better. The cause of the poor visual outcome in many patients was preexisting amblyopia. CONCLUSIONS: The results suggest that 4-point scleral fixation is an option to correct aphakia in children. However, long-term follow-up is important to assess the procedure's safety.
Lack of <i>FOXE3</i> coding mutation in a case of congenital aphakia
AbstractPURPOSE: To report the findings in a patient with congenital primary aphakia, a rare disease known to be caused by mutations in the FOXE3 gene. METHODS: The clinical appearances and visual functions of the patient were determined from the medical records. Genetic analyses were performed to search for mutations in the FOXE3 gene by Sanger sequencing and whole exome sequencing. RESULTS: The 2-month-old male patient first presented with bilateral congenital aphakia associated with microphthalmia, corneal opacity, and dysplasia of the anterior segment. At the age of 2-years, his visual acuity in the left eye was 20/1000 at 30 cm, he was able to discriminate red, blue, and yellow light stimuli, and a b-wave was recorded by scotopic combined rod-cone electroretinograms. The right eye became blind during the follow-up period. No mutation in the FOXE3 gene was detected. CONCLUSION: Although congenital aphakia is known to be caused by mutations in the FOXE3 gene, the results of lack of coding mutation in this patient suggests a possible genetic heterogeneity of the disease.
Thrombocytopenia and absent radii syndrome with type III phocomelia and orthopaedic management
AbstractThrombocytopenia with radial aplasia (TAR) syndrome is a rare congenital defect with skeletal system abnormalities accompanied usually by cardiac, hematological and gastrointestinal system abnormalities. Our case is a 6-month old infant with TAR-syndrome who also has type III distal phocomelia in which the hand is attached directly to humerus without a forearm segment. Patients with TAR syndrome and phocomelia are not described in literature. Spontaneous remission is expected after 12 months if the thrombocytopenia crisis&#039; are supported by thrombocyte transfusions. These patients have good prognosis for longevity. Whole blood count should be performed for the infants with radius aplasia at birth to assess the correct diagnosis of this syndrome. The treatment of orthopaedic problems in TAR syndrome should be planned after the first year when the spontaneous remission is achieved.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
